Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines’ shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX (OTCQX: TRNLY).

The Trendlines Group announced today that during 2018 and the first six months of 2019 five of its portfolio companies were chosen to receive prestigious Horizon 2020 grants.

Horizon 2020 is “the biggest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020) – in addition to the private investment that this money will attract. It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.”

Only a small percentage of applicants receive grants for “world-class science,” company leadership, and solutions that “tackle societal challenges.”

According to an EU study released in December 2017, only 12.6% of applications were approved in the program’s first three years.

Through the program, Israeli researchers, start-ups, and innovators have gained access to European partners and the extensive European research infrastructure.

These Trendlines portfolio companies received Horizon 2020 grants, each exceeding € 1 million:

Saturas Ltd. developed an Advanced Decision Support System (ADSS) for precision irrigation based on its miniature Stem Water Potential (SWP) sensor.

GreenSpense Ltd. developed a gas-free, high-pressure continuous dispensing solution based on breakthroughs in elastomer technology and materials engineering.

ElastiMed Ltd. developed a device using smart material-based technology mimicking rhythmic calf muscle contractions to improve circulation.

ProArc Medical Ltd. developed the ClearRing solution intended to treat symptoms due to urinary outflow obstruction caused by enlarged prostate also known as BPH (Benign Prostatic Hyperplasia).

liberDi Ltd. developed an all-in-one portable dialysis device providing scalable digital and safe self-care anywhere.

steverhodes talk1.16Trendlines Chairman & CEO Steve Rhodes.
NextInsight file photo.
Trendlines Chairman and CEO Steve Rhodes commented, “We’re extremely proud of the companies that received non-dilutive funding grants through Horizon 2020 indicating a strong endorsement of their technological progress and promise. The grants affirm the companies’ excellence and innovation in their respective fields and provide funding to assist them in bringing their technologies to market.”

You may also be interested in:

You have no rights to post comments


We have 2498 guests and no members online

rss_2 NextInsight - Latest News